

## Prof. SERCAN AKSOY

### Personal Information

**Office Phone:** [+90 312 305 2929](tel:+903123052929)

**Email:** saksoy@hacettepe.edu.tr

**Web:** <https://avesis.hacettepe.edu.tr/saksoy>

**Address:** 06100

### International Researcher IDs

ORCID: 0000-0003-4984-1049

Publons / Web Of Science ResearcherID: J-1232-2013

ScopusID: 7006512389

Yoksis Researcher ID: 186589

### Education Information

Post Doctorate of Medicine, Hacettepe University, İç Hastalıkları Abd, Tıbbi Onkoloji Bilim Dalı, Turkey 2002 - 2006

Post Doctorate of Medicine, Hacettepe University, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı- Medikal Onkoloji Bilim Dalı, Turkey 2002 - 2006

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Turkey 1997 - 2002

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, İç Hastalıkları Abd, Turkey 1997 - 2002

Doctorate, Hacettepe University, Tıp Fakültesi, Turkey 1990 - 1997

### Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

### Academic Titles / Tasks

Professor, Hacettepe University, Kanser Enstitüsü, Klinik Onkoloji Anabilim Dalı, 2014 - Continues

Associate Professor, Hacettepe University, Kanser Enstitüsü, 2012 - 2014

Lecturer, Hacettepe University, Kanser Enstitüsü, 2006 - 2010

### Academic and Administrative Experience

Hacettepe Üniversitesi, Kanser Enstitüsü, 2013 - 2016

Hacettepe Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2013 - 2014

### Published journal articles indexed by SCI, SSCI, and AHCI

- Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY**  
Balmaña J, Fasching P. A., Couch F. J., Delaloge S., Labidi-Galy I., O'Shaughnessy J., Park Y. H., Eisen A. F., You B., Bourgeois H., et al.

Breast Cancer Research and Treatment, vol.204, no.2, pp.237-248, 2024 (SCI-Expanded)

- II. **The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study**  
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., Şakalar T., Celayir Ö. M., KAYIKÇIOĞLU E., Aslan F., et al.  
International Journal of Clinical Oncology, vol.29, no.3, pp.258-265, 2024 (SCI-Expanded)
- III. **Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study**  
YILDIRIM H. Ç., Kapar C., KÖKSAL B., Seyyar M., Sancı P. C., Guliyev M., Perkin P., Buyukkor M., YASLIKAYA Ş., Majidova N., et al.  
Journal of Chemotherapy, 2024 (SCI-Expanded)
- IV. **Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial**  
Machiels J., Tao Y., Licitra L., Burtness B., Tahara M., Rischin D., Alves G., Lima I. P. F., Hughes B. G. M., Pointreau Y., et al.  
The Lancet Oncology, 2024 (SCI-Expanded)
- V. **Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis**  
GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., AKSOY S.  
Laryngoscope, vol.134, no.1, pp.7-17, 2024 (SCI-Expanded)
- VI. **Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer**  
Saatci O., Cetin M., ÜNER M., Tokat U. M., Chatzistamou I., Ersan P. G., Montaudon E., AKYOL A., AKSOY S., ÜNER A., et al.  
Nature Communications, vol.14, no.1, 2023 (SCI-Expanded)
- VII. **Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia**  
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., GÜNER G., GÜVEN D. C., ARIK Z., KERTMEN N., et al.  
Current Oncology, vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded)
- VIII. **Molecularly imprinted electrochemical sensor for the selective and sensitive determination of octreotide in cancer patient plasma sample**  
Ozkan E., Ozcelikay G., Gök Topak E. D., NEMUTLU E., ÖZKAN S. A., DİZDAR Ö., AKSOY S., KIR S.  
Talanta, vol.263, 2023 (SCI-Expanded)
- IX. **Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives**  
ERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.  
European Archives of Oto-Rhino-Laryngology, vol.280, no.8, pp.3541-3556, 2023 (SCI-Expanded)
- X. **GLIM criteria as a valid tool for nutrition assessment and mortality prediction in treatment-naïve patients with cancer**  
BALCI C., Tufan G., Özdemir N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., Kars A., Halil M.  
Nutrition in Clinical Practice, vol.38, no.4, pp.798-806, 2023 (SCI-Expanded)
- XI. **Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer**  
Şener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., ÖZET A., AKSOY S., Tezel Y. G. G., Akyürek N., et al.  
Strahlentherapie und Onkologie, vol.199, no.8, pp.761-772, 2023 (SCI-Expanded)
- XII. **The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center**

**retrospective cohort study**

GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., AKSOY S., ERMAN M., YALÇIN Ş., ÜRÜN Y., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded)

- XIII. **The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors**  
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., YILDIRIM H. Ç., Chalabiyev E., Cebroyilov C., YILDIRIM T., et al.  
Anti-Cancer Drugs, vol.34, no.6, pp.783-790, 2023 (SCI-Expanded)
- XIV. **Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial**  
André F., Hee Park Y., Kim S., Takano T., Im S., Borges G., Lima J. P., AKSOY S., Gavila Gregori J., De Laurentiis M., et al.  
The Lancet, vol.401, no.10390, pp.1773-1785, 2023 (SCI-Expanded)
- XV. **Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort**  
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., Chalabiyev E., KUŞ F., YALÇIN Ş., AKSOY S.  
Medicine (United States), vol.102, no.18, 2023 (SCI-Expanded)
- XVI. **The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma**  
GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., Kaygusuz Y., ÇAYIRÖZ K., ÜÇDAL M. T., Yesil F., et al.  
European Archives of Oto-Rhino-Laryngology, vol.280, no.5, pp.2471-2478, 2023 (SCI-Expanded)
- XVII. **Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification**  
Saatci O., Akbulut O., Cetin M., Sikirzhytski V., ÜNER M., LENERLİ D., O'Quinn E. C., Romeo M. J., ÇALIŞKAN B., BANOĞLU E., et al.  
Cell Death and Differentiation, vol.30, no.5, pp.1305-1319, 2023 (SCI-Expanded)
- XVIII. **Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group**  
DOĞAN İ., AKSOY S., Cakar B., BAŞARAN G., Ercelep O., Molinas Mandel N., KORKMAZ T., Gokmen E., Sener C., AYDINER A., et al.  
Cancers, vol.15, no.6, 2023 (SCI-Expanded)
- XIX. **Post-induction lymph node delineation in nasopharyngeal cancer: A single-center experience.**  
Sari S., YİĞİT E., YAZICI G., GÜLLÜ İ. H., AKSOY S., ÖZYİĞİT G., CENGİZ M.  
Head & neck, vol.45, no.3, pp.612-619, 2023 (SCI-Expanded)
- XX. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer**  
Kahraman S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., Acar O., AKSOY S., Baytemur N. K., ŞAHİN E., et al.  
Future oncology (London, England), vol.19, no.10, pp.727-736, 2023 (SCI-Expanded)
- XXI. **Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy**  
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., YÜCE D., ARIK Z., KILIÇKAP S., AKSOY S., et al.  
INTERNATIONAL JOURNAL OF CANCER, vol.152, pp.679-685, 2023 (SCI-Expanded)
- XXII. **Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy**  
Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avşar E., Paksoy N., et al.  
BMC cancer, vol.23, no.1, pp.136, 2023 (SCI-Expanded)

- XXIII. **Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment**  
Güven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., AKSOY S.  
Expert Review of Anticancer Therapy, vol.23, no.10, pp.1049-1059, 2023 (SCI-Expanded)
- XXIV. **Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma**  
ERUL E., Güven D. C., ÖZBAY Y., ALTUNBULAK A. Y., KAHVECİOĞLU A., ERCAN F., Yesil M. F., ÜÇDAL M. T., CENGİZ M., YAZICI G., et al.  
Biomarkers in medicine, vol.17, no.2, pp.87-99, 2023 (SCI-Expanded)
- XXV. **The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis**  
GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., YALÇIN Ş.  
Frontiers in Molecular Biosciences, vol.9, 2022 (SCI-Expanded)
- XXVI. **Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study**  
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., Celebi A., DURSUN B., Acar O., KAHRAMAN S., et al.  
BREAST, vol.66, pp.85-88, 2022 (SCI-Expanded)
- XXVII. **Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49**  
Schmid P., Sohn J. H., Jerez Gilarranz Y., Gonzalez-Cortijo L., Sonnenblick A., Sabanathan D., Korbenfeld E., Egle D., Poirier B., Zagouri F., et al.  
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol.18, pp.233-234, 2022 (SCI-Expanded)
- XXVIII. **Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis**  
BAŞ O., Erul E., GÜVEN D. C., AKSOY S.  
SUPPORTIVE CARE IN CANCER, vol.30, no.11, pp.9071-9078, 2022 (SCI-Expanded)
- XXIX. **The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges**  
GÜVEN D. C., ŞAHİN T. K., Rizzo A., Ricci A. D., AKSOY S., ŞAHİN K.  
APPLIED SCIENCES-BASEL, vol.12, no.20, 2022 (SCI-Expanded)
- XXX. **Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease**  
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKSOY S., ERMAN M., KILICKAP S., YALÇIN Ş.  
JOURNAL OF CLINICAL MEDICINE, vol.11, no.17, 2022 (SCI-Expanded)
- XXXI. **The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy**  
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., AKTEPE O. H., ERMAN M., KILIÇKAP S., AKSOY S., et al.  
JOURNAL OF CLINICAL MEDICINE, vol.11, no.15, 2022 (SCI-Expanded)
- XXXII. **Optimization and normalization strategies for long term untargeted HILIC-LC-qTOF-MS based metabolomics analysis: Early diagnosis of breast cancer**  
REÇBER T., NEMUTLU E., Beksac K., CENNET Ö., Kaynaroglu V., AKSOY S., KIR S.  
MICROCHEMICAL JOURNAL, vol.179, 2022 (SCI-Expanded)
- XXXIII. **The effects of systemic aromatase inhibitors on meibomian glands and corneal structure**  
Agin A., KOCABEYOĞLU S., Gencoglu A. Y., AKSOY S., KARAKAYA KARABULUT J., Irkeç M.  
EYE, vol.36, no.6, pp.1185-1193, 2022 (SCI-Expanded)
- XXXIV. **The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy**  
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., ERMAN M., KILIÇKAP S., YALÇIN Ş.

- JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.4, pp.785-793, 2022 (SCI-Expanded)
- XXXV. **The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis**  
GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.  
CANCERS, vol.14, no.11, 2022 (SCI-Expanded)
- XXXVI. **The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials**  
GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., Erul E., AKSOY S.  
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.174, 2022 (SCI-Expanded)
- XXXVII. **Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer**  
YEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.  
JOURNAL OF CLINICAL MEDICINE, vol.11, no.9, 2022 (SCI-Expanded)
- XXXVIII. **Liquid biopsy markers for early diagnosis of brain metastasis patients with breast cancer by metabolomics**  
Ozer O., NEMUTLU E., REÇBER T., Eylem C. C., AKTAŞ B. Y., KIR S., Kars A., AKSOY S.  
EUROPEAN JOURNAL OF MASS SPECTROMETRY, vol.28, no.1-2, pp.56-64, 2022 (SCI-Expanded)
- XXXIX. **HER2-low breast cancer could be associated with an increased risk of brain metastasis**  
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMHEMETOĞLU K., KERTMEN N., DİZDAR Ö., ÜNER A., AKSOY S.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.27, no.2, pp.332-339, 2022 (SCI-Expanded)
- XL. **p New Perspectives on the Recurrent BRCA Mutations and Clinical Variability**  
Sahin I., Saat H., AKSOY S.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.32, no.1, pp.44-49, 2022 (SCI-Expanded)
- XLI. **The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study**  
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., KERTMEN N., DİZDAR Ö., AKSOY S.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded)
- XLII. **18F FDG PET/CT after Neoadjuvant Chemotherapy and Pathological Responses are Predictive Factors for Disease-Free Survival and Overall Survival in Patients with Locally Advanced Breast Cancer: A Prospective Study**  
Kupik O., TUNCEL M., AKSOY S., Kiratli P. O., GÜLSÜN AKPINAR M., Altundag K., DEMİRKAZIK F., Erbas B.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.32, no.3, pp.150-158, 2022 (SCI-Expanded)
- XLIII. **Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience**  
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., GÜVEN D. C., Olgun P., KERTMEN N., DİZDAR Ö., et al.  
FUTURE ONCOLOGY, vol.18, pp.323-331, 2022 (SCI-Expanded)
- XLIV. **Upper limb sensory evaluations and ultrasonographic skin measurements in breast cancer-related lymphedema receiving complex decongestive physiotherapy**  
BARAN E., ÖZÇAKAR L., ÖZGÜL S., AKSOY S., AKBAYRAK T.  
SUPPORTIVE CARE IN CANCER, vol.29, no.11, pp.6545-6553, 2021 (SCI-Expanded)
- XLV. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**  
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., ÜÇGÜL E., AKSUN M. S., GÜRBÜZ S. Ç., AKTEPE O. H., et al.  
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- XLVI. **Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review**  
Oguz S. H., ÜNLÜTÜRK U., AKSOY S., Erbas T.  
IMMUNOTHERAPY, vol.13, no.14, pp.1157-1164, 2021 (SCI-Expanded)
- XLVII. **Sarcopenia and anthracycline cardiotoxicity in patients with cancer**

BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., BARIŞTA İ., GÜNER G., GÜVEN D. C., KERTMEN N., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)

**XLVIII. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.

SUPPORTIVE CARE IN CANCER, vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded)

**XLIX. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors**

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., ŞAHİN T. K., AKSUN M. S., DİZDAR Ö., AKSOY S., et al.

BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded)

**L. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES**

Im Y., KARABULUT B., Lee K. S., Park B., Adhav A., Cinkir H. Y., Abdel-Razeq H., Chang Y., AKSOY S., Im S., et al.

BREAST CANCER RESEARCH AND TREATMENT, vol.188, no.1, pp.77-89, 2021 (SCI-Expanded)

**LI. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY**

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., YILDIRIM T., DİZDAR Ö., AKSOY S., KILIÇKAP S., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, 2021 (SCI-Expanded)

**LII. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience**

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., TABAN H., GÜVEN D. C., KERTMEN N., Oksuzoglu B., et al.

CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)

**LIII. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen**

ŞENDUR M. A. N., Ozdemir N., Ozatli T., Yazici O., AKSOY S., Ekinci A. S., Yazilitas D., Gunaydin Y., Oksuzoglu B., BENEKLİ M., et al.

MEDICAL ONCOLOGY, vol.31, no.9, 2014 (SCI-Expanded)

**LIV. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study**

BİLİCİ A., ÖLMEZ Ö. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., ÇUBUKÇU E., Sendur M. A. N., AKSOY S., Erdem D., et al.

Acta Oncologica, vol.62, no.4, pp.381-390, 1 (SCI-Expanded)

## Articles Published in Other Journals

**I. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab**

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., AKSOY S., ERMAN M., YALÇIN Ş., Kilickap S. Journal of Immunotherapy and Precision Oncology, vol.6, no.4, pp.170-176, 2023 (Scopus)

**II. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer**

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., AKYILDIZ A., YILMAZ F., YAŞAR S., Evlendi Y., et al.

Journal of Oncological Science, vol.9, no.1, pp.33-37, 2023 (Scopus)

**III. The Comparative Frequency of Breast Cancer-Related Lymphedema Determined by Bioimpedance**

### **Spectroscopy and Circumferential Measurements**

Borman P., Yaman A., Dogan L., Donmez A. A., KOYUNCU E. G., BALCAN A., AKSOY S., Ozaslan C., Akin R., Unes K. EUROPEAN JOURNAL OF BREAST HEALTH, vol.18, no.2, pp.148-154, 2022 (ESCI)

#### **IV. The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors**

Dişel U., Köse F., Bilici A., ÖZGÜROĞLU M., Sağlam S., ŞEKER M., AKSOY S., Tek İ., Mandel N. M., Demir G., et al. Journal of Oncological Science, vol.8, no.2, pp.87-93, 2022 (Scopus)

#### **V. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)

#### **VI. Liquid biopsy: Novel perspectives on the importance and spectrum of PIK3CA, PTEN and RET mutations in solid tumors**

Sahin I., Saat H., AKSOY S., DİZDAR Ö., Erdem H. B., Bahsi T.

MOLECULAR AND CLINICAL ONCOLOGY, vol.16, no.1, 2022 (ESCI)

#### **VII. Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review**

Yigit E., GÜVEN D. C., AKSOY S., YAZICI G.

CUREUS, vol.13, no.6, 2021 (ESCI)

### **Books & Book Chapters**

#### **I. Systemic Therapies in the Management of Testicular Cancers**

ŞENDUR M. A. N., AKSOY S.

in: Principles and Practice of Urooncology Radiotherapy, Surgery and Systemic Therapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editor, Springer, 2017

#### **II. Targeted Therapies and Immunotherapy in Bladder Cancer**

ŞENDUR M. A. N., AKSOY S.

in: Principles and Practice of Urooncology Radiotherapy, Surgery and Systemic Therapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editor, Springer, pp.141-152, 2017

#### **III. Kanser ve Kalp Yetmezliği**

ŞENDUR M. A. N., AKSOY S.

in: Kalp Yetmezliği Cep Kitabı, Prof. Dr. Ali Oto, Prof. Dr. Barış Kaya, Prof Dr. Kudret Aytemir, Editor, Erkem Tıbbi Yayıncılık, 2016

#### **IV. Systemic Therapies in Malignant Pleural Mesothelioma**

Yazıcı O., AKSOY S.

in: Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gokhan Ozyigit, Ugur Selek, Erkan Topkan, Editor, Springer, pp.469-481, 2016

#### **V. Current Systemic Therapy Options for Head and Neck Cancer**

ŞENDUR M. A. N., AKSOY S.

in: Radiation Therapy for Head and Neck Cancers A Case Based Review, Murat Beyzade, Gökhan Ozyigit, ugur Selek, Editor, Springer, 2015

### **Refereed Congress / Symposium Publications in Proceedings**

#### **I. Overcoming chemotherapy resistance in triple negative breast cancer via targeting lysyl oxidase (LOX)**

Saatçi Ö., Akbulut Ö., Rezaeain A., Banister C., Sikirzhyski V., AKSOY S., AKYOL A., ÜNER A., Buckhaults P., Chernov

M., et al.

AACR Virtual Special Conference, Virtual, United States Of America, 11 - 12 January 2021, vol.81

- II. **Detection of brain metastasis by metabolomics methods in metastatic breast cancer patients.**  
Özer Ö., NEMUTLU E., Eylem C. C., KIR S., REÇBER T., Aktas B. Y., Kars A., AKSOY S.  
2019 ASCO Annual Meeting, United States Of America, 30 May - 03 June 2019, vol.37, pp.12572
- III. **The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.**  
Yildirim B., Cem O., Kose F., Oymak E., Sedef A. M., Besen A. A., Aksoy S., Guler O. C., Sumbul A. T., Mertsoylu H., et al.  
ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Costa Rica, 28 February - 02 March 2019, vol.37
- IV. **The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.**  
Cem O., Sedef A. M., Kose F., Oymak E., Guler O. C., Sumbul A. T., Aksoy S., Yildirim B. A., Besen A. A., Mullaoglu S., et al.  
ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Costa Rica, 28 February - 02 March 2019, vol.37
- V. **KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma**  
Siu L. L., Licitra L., Tao Y. G., Yen C., Rischin D., Waldron J., Burtness B., Gregoire V., Agarwala S., Yorjo J., et al.  
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Illinois, United States Of America, 14 - 18 April 2018, vol.78
- VI. **Trace-Level Determination of 2-Amino Adipic Acid by LC-ESI-MS/MS for Early Diagnosis of Breast Cancer**  
REÇBER T., AKSOY S., NEMUTLU E., KIR S.  
International Trace Analysis Congress, 20 - 23 June 2018
- VII. **Mass Spectrometry Based Targeted and Untargeted Metabolomic Analysis for Early Diagnosis of Breast Cancer Using LC-ESI-qTOF-MS and LC-ESI-MS/MS**  
REÇBER T., AKSOY S., BEKSAÇ K., CENNET Ö., KAYNAROĞLU Z. V., NEMUTLU E., KIR S.  
8TH 8th BLACK SEA BASIN CONFERENCE ON ANALYTICAL CHEMISTRY, 9 - 11 May 2018
- VIII. **Adjuvan Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanseri Olgularında Tedavi Sonuçlarımız.**  
YÜCE SARI S., CENGİZ M., YAZICI G., ELMALI DOĞAN A., BEDÜK Ç. S., GÜLLÜ İ. H., AKSOY S., ÖZYİĞİT G.  
13.Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 27 April - 01 May 2018
- IX. **Baş-Boyun Melanomlarında Radyoterapi Sonuçlarımız**  
YÜCE SARI S., YAZICI G., CENGİZ M., YILMAZ M. T., AKSOY S., GÜLLÜ İ. H., ÖZYİĞİT G.  
13. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Turkey, 27 April - 01 May 2018
- X. **Metastatik NUT Midline Karsinomunda İmmünoterapi ve Reirradiasyon: Vaka Sunumu.**  
ELMALI DOĞAN A., YILMAZ M. T., AKSOY S., YÜCE SARI S., ÖZYİĞİT G., YAZICI G.  
13.Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 27 April - 01 May 2018
- XI. **GERİATRİK POPÜLASYONDAKİ YENİ TANIONKOLOJİK VAKALARDA MALNUTRİSYON VESARKOPENİ SIKLIĞI: ÇOK MERKEZLİ-KESİTSELÇALIŞMA**  
BALCI C., Tufan G., ÖZDEMİR N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., KARS S. A., HALİL M. G.  
11. Akademik Geriatri Kongresi, Antalya, Turkey, 19 - 23 April 2018
- XII. **High Prevalence of Malnutrition and Sarcopenia in Newly Diagnosed Cancer Patients in Turkey: Multicenter, Cross Sectional Study**  
BALCI C., Tufan G., ÖZDEMİR N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., KARS S. A., HALİL M. G.  
ASPEN 2018, Las-Vegas, United States Of America, 22 - 25 January 2018
- XIII. **Bağışıklık sistemi baskılanmış hastalarda Microsporidia ve fırsatçı bağırsak parazitlerinin varlığının araştırılması**  
Kaya F., İNKAYA A. Ç., AKSOY S., ABBASOĞLU O., ERTENLİ A. İ., BÜYÜKAŞIK Y., ARIKAN AKDAĞLI S., AKYÖN YILMAZ Y., ERGÜVEN S.  
4. Ulusal Klinik Mikrobiyoloji Kongresi, Turkey, 8 - 12 November 2017
- XIV. **TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ**  
KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., SARICI F., ATEŞ Ö., ALTUNDAĞ M. K.



22. UKK, Turkey, 19 - 23 April 2017

- XV. **Impact of vitamin D3 replacement therapy on clinical outcomes and survival rates in patients with early stage breast cancer**  
YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., ZENGİN N., ALTUNDAĞ M. K.  
ESMO 2016, 7 - 11 October 2016
- XVI. **Role of glutamine for preventing oxaliplatin induced peripheral neuropathy GELUPO results of randomized open label phase II trial**  
Yazıcı O., Titiz A., ÖZDEMİR N., AKSOY S., ŞENDUR M. A. N., Arlı B., ZENGİN N.  
ESMO 2016, 7 - 11 October 2016
- XVII. **Effect of polypharmacy on treatment preferences and outcome in older breast cancer patients**  
ŞENDUR M. A. N., SILAY K., AKSOY S., Özbek S., ÖZDEMİR N., ALTUNDAĞ M. K.  
ESMO 2016, 7 - 11 October 2016
- XVIII. **Effect of using different antihypertensive drugs on demographic and clinicopathological characteristics of breast cancer**  
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., Yazıcı O., AKINCI M. B., ŞENER DEDE D., YALÇIN B., ZENGİN N., ALTUNDAĞ M. K.  
ESMO 2016, 7 - 11 October 2016
- XIX. **Effect of body mass index in the outcome of stage I-III triple negative breast cancer**  
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., Yazıcı O., ZENGİN N., ALTUNDAĞ M. K.  
ESMO 2016, 7 - 11 October 2016
- XX. **Effect of using different antidiabetic drugs on demographic and clinicopathological characteristics of breast cancer**  
ŞENDUR M. A. N., AKSOY S., Yazıcı O., ÖZDEMİR N., ŞENER DEDE D., AKINCI M. B., YALÇIN B., ZENGİN N., ALTUNDAĞ M. K.  
ESMO 2016, 7 - 11 October 2016
- XXI. **Survival and Larynx Preservation Rates after Definitive Radiotherapy A Single Center Experience**  
CENGİZ M., YÜCE SARI S., GÜLTEKİN M., SÜSLÜ N., AKSOY S., KUŞCU O., ÖZYİĞİT G., HOŞAL Ş., HAYRAN K. M., GÜLLÜ İ. H.  
ECHO 2016, Budapest, Hungary, 7 - 10 September 2016
- XXII. **Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma**  
ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., TÜRKER F. A., KARS S. A.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXIII. **The impact of the total size of lesions in multifocal multicentric breast cancer on survival**  
Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., GÜLLÜ İ. H., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXIV. **Comparison of clinical outcomes in patients with early stage ER PR HER2 breast cancer patients with triple negatives**  
Erdem G. U., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Doğan M., ZENGİN N., ALTUNDAĞ M. K.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXV. **Intravenous ferric carboxymaltose treatment in cancer patients**  
ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXVI. **Modified docetaxel cisplatin and fluorouracil therapy as a first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer a retrospective study**  
DEMİRCİ N., AKSOY S., ÖZDEMİR N., Babacan T., ERDEM G. U., BOZKAYA Y., ZENGİN N., GÜLLÜ İ. H.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXVII. **SEROLOGICAL DETECTION OF STRONGYLOIDES STERCORALIS INFECTION IN IMMUNOSUPPRESSED PATIENTS: HACETTEPE EXPERIENCE**  
DEMİREL KAYA F., ERTENLİ A. İ., İNKAYA A. Ç., ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., ERGÜVEN S.  
9TH BALKAN CONGRESS OF MICROBIOLOGY, SELANİK, Greece, 22 - 24 October 2015
- XXVIII. **Serological Detection of Strongyloides stercoralis infection in immunosuppressed patients Hacettepe**

## Experience

Kaya F., ERTENLİ A. İ., İNKAYA A. Ç., ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., ERGÜVEN S.

Acta Microbiologica Hellenica (9th Balkan Congress of Microbiology), 22 - 24 October 2015

- XXIX. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**  
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., KARAKAS Y., KILIÇKAP S., AKSOY S., ÖZİŞİK Y. Y., et al.  
ASCO Annual Meeting, 29 May - 02 June 2015
- XXX. **Tumor locations significantly affect disease free survival and overall survival**  
BUYUKHATİPOĞLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., AKSOY S., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXXI. **Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoğlu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever**  
ALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOĞLU H., BALAKAN O., SARICI F. S., KERTMEN N., ESİN E., et al.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXXII. **Brain specific progression free survival bsPFS according to breast cancer subtypes in patients with brain metastases**  
ARSLAN Ç., YAZICI O., AKSOY S., ALTUNDAĞ M. K.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXXIII. **Study of the impact of Charlson comorbidity index on the efficacy of aromatase inhibitors in patients with hormone receptor positive postmenopausal breast cancer**  
ŞENDUR M. A. N., AKSOY S., SILAY K., AKINCI M. B., ÖZDEMİR N., YAZICI O., ÖZBEK S., ZENGİN N., YALÇIN B., ALTUNDAĞ M. K.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXXIV. **Neuroendocrine breast cancer A single center experience**  
TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., DİZDAR Ö., AKSOY S., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXXV. **The role of the gastrectomy on survival in metastatic gastric cancer patients: A multicenter study of Anatolian Society of Medical Oncology (ASMO)**  
Yazici O., Ozdemir N., Duran A. O., Menekse S., Sendur M. A. N., Karaca H., Goksel G., Arpacı E., Eren T., Hacibekiroğlu I., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXVI. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.**  
Altundag K., Babacan T., Efe O., Hasırcı A. S., Demirci F., Buyukhatıpoğlu H., Balakan O., Sarıcı F. S., Kertmen N., Esin E., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXVII. **Efficacy of adjuvant tamoxifen in hormone receptor-positive premenopausal breast cancer patients according to the body mass index**  
Altundag K., Sendur M. A. N., AKSOY S., BABACAN T., Ozisik Y.  
37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 13 December 2014, vol.75
- XXXVIII. **Comparison of long-term cardiac effects of 9-and 52-week trastuzumab in HER2-positive early**

**breast cancer.**

Sendur M. A. N., Aksoy S., Ozdemir N., Yorgun H., Yilmaz F. M., Yazici O., Zungun C., Aytemir K., Altundag K., Zengin N.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03  
June 2014, vol.32

**XXXIX. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.**

Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., Sarici S. F., Akin S., Altundag K., Gullu I. H.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03  
June 2014, vol.32

**XL. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats**

Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., Babacan T., Sarici S. F., Sendur M. A. N., Arik Z., et al.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03  
June 2014, vol.32

**XLI. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.**

Yetisyigit T., Babacan N., Urun Y., Seber S., Arpacı E., Clhan S., Ylirim N., Oksuzoglu O. B., Aksoy S., Budakoglu B., et al.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03  
June 2014, vol.32

**XLII. Effect of body mass index on metastatic pattern in early breast cancer patients.**

Yazici O., Aksoy S., Sendur M. A. N., Ozdemir N., Zengin N., Altundag K.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03  
June 2014, vol.32

**XLIII. Retrospective analysis of 178 patients with stage I rectum cancer.**

Cihan S., Ozdemir N., Urakci Z., Kucukoner M., Dane F., Yazilitas D., Durnali A., Yuksel S., Colak D., Seker M., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31  
May - 04 June 2013, vol.31

**XLIV. Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.**

Altundag K., Aksoy S., Sendur M. A. N., Guler E. N., Gullu I. H., Ozisik Y. Y.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31  
May - 04 June 2013, vol.31

**XLV. Inflammatory markers in metastatic breast cancer.**

Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C., Sarici S. F., Arslan C., Arik Z., Aksoy S., Altundag K.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31  
May - 04 June 2013, vol.31

**XLVI. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.**

Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., Arik Z., Yaman S., Eren T., Uncu D., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31  
May - 04 June 2013, vol.31

**XLVII. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.**

Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C., Babacan T., Sahin U., Keskin O., Kertmen N., Aksoy S., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31  
May - 04 June 2013, vol.31

**XLVIII. Metformin in diabetic pancreatic cancer patients: Benefit or not-Multicenter experience.**

Esbah O., Oksuzoglu B., Eren T., Helvacı K., Guler T., Duran A. O., Bal O., Ozdemir N. Y., Aksoy S.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04  
June 2013, vol.31

**XLIX. Retrospective review of modified dose docetaxel, cisplatin, and 5-flourouracil (DCF) for the treatment of first-line metastatic gastric carcinomas.**

Ozdemir N., Aksoy S., Eren T., Abali H., Oksuzoglu O. B., Zengin N.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

- L. **Comparison of the efficacy of adjuvant letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.**  
Sendur M. A. N., Aksoy S., Altundag K.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LI. **Clinicopathologic characteristics of pure papillary breast carcinoma**  
Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., Aksoy S., Altundag K.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LII. **Demographic and clinicopathologic characteristics in patients with invasive breast cancer receiving metformin.**  
Aksoy S., Sendur M. A. N., Altundag K.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LIII. **The number of metastatic lymph node in N3M0 breast cancer and influence on survival.**  
Solak M., Turkoz F. P., Keskin O., Petekkaya H., Sarici S. F., Babacan T., Esin E. C. E., Aksoy S., Altundag K.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LIV. **Inflammatory markers in early-stage breast cancer.**  
Petekkaya H., Aksoy S., Gecmez G., Kulahcioglu E., Okoh A. K., Isler D. C., Demirci A. F., Sahin U., Dogan E., Altundag K.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LV. **Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.**  
Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., Rahatli S., Dede D. S., Altundag O., Zengin N., et al.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- LVI. **Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use**  
Aksoy S., Sendur M. A. N., Yaman S., Arik Z., Ozdemir N., Zengin N., Altundag K.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- LVII. **Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?**  
Yaman S., Aksoy S., Sendur M. A. N., Arik Z., Ozdemir N., Zengin N., Altundag K.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- LVIII. **Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.**  
Sendur M. A. N., Aksoy S., Yaman S., Kos F. T., Arik Z., Civelek B., Ozdemir N., Uncu D., Zengin N.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- LIX. **Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.**  
Arik Z., Aksoy S., Sendur M. A. N., Yaman S., Altundag K.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- LX. **Cigarette smoking and risk of pulmonary metastasis from breast cancer**  
Aksoy S., Altundag K., Ozisik Y., Guler N., Gullu I., Kars A., Turker A., Tekuzman G.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.102

**LXI. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma**

Kilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., Erman M., Aytemir K., Tokgozoglu L., Barista I.  
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.202

## **Supported Projects**

AKSOY S., Project Supported by Higher Education Institutions, Hemşireler İçin Temel Palyatif Bakım Kursu, 2014 - 2020

## **Metrics**

Publication: 277

Citation (WoS): 1456

Citation (Scopus): 2184

H-Index (WoS): 19

H-Index (Scopus): 23

## **Non Academic Experience**

SAĞLIK BAKANLIĞI